Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.

Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV, Emens LA.

Hum Gene Ther. 2018 May;29(5):614-625. doi: 10.1089/hum.2017.080. Epub 2018 Apr 2.

2.

CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease.

De Ravin SS, Li L, Wu X, Choi U, Allen C, Koontz S, Lee J, Theobald-Whiting N, Chu J, Garofalo M, Sweeney C, Kardava L, Moir S, Viley A, Natarajan P, Su L, Kuhns D, Zarember KA, Peshwa MV, Malech HL.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaah3480. doi: 10.1126/scitranslmed.aah3480.

PMID:
28077679
3.

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19.

Carlsten M, Levy E, Karambelkar A, Li L, Reger R, Berg M, Peshwa MV, Childs RW.

Front Immunol. 2016 Mar 22;7:105. doi: 10.3389/fimmu.2016.00105. eCollection 2016.

4.

Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease.

De Ravin SS, Reik A, Liu PQ, Li L, Wu X, Su L, Raley C, Theobald N, Choi U, Song AH, Chan A, Pearl JR, Paschon DE, Lee J, Newcombe H, Koontz S, Sweeney C, Shivak DA, Zarember KA, Peshwa MV, Gregory PD, Urnov FD, Malech HL.

Nat Biotechnol. 2016 Apr;34(4):424-9. doi: 10.1038/nbt.3513. Epub 2016 Mar 7.

5.

Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL.

Wolfraim LA, Takahara M, Viley AM, Shivakumar R, Nieda M, Maekawa R, Liu LN, Peshwa MV.

Int Immunopharmacol. 2013 Mar;15(3):488-97. doi: 10.1016/j.intimp.2013.01.009. Epub 2013 Feb 8.

PMID:
23474736
6.

Large volume flow electroporation of mRNA: clinical scale process.

Li L, Allen C, Shivakumar R, Peshwa MV.

Methods Mol Biol. 2013;969:127-38. doi: 10.1007/978-1-62703-260-5_9. Review.

PMID:
23296932
7.

Efficient large volume lentiviral vector production using flow electroporation.

Witting SR, Li LH, Jasti A, Allen C, Cornetta K, Brady J, Shivakumar R, Peshwa MV.

Hum Gene Ther. 2012 Feb;23(2):243-9. doi: 10.1089/hum.2011.088. Epub 2011 Oct 24.

8.

Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.

Okur FV, Yvon E, Biagi E, Dotti G, Carrum G, Heslop H, Mims MP, Fratantoni JC, Peshwa MV, Li L, Brenner MK.

Cytotherapy. 2011 Oct;13(9):1128-39. doi: 10.3109/14653249.2011.592523. Epub 2011 Jul 12.

9.

Dendritic cell-based treatment of cancer: closing in on a cellular therapy.

Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R.

Cancer J. 2001 Nov-Dec;7 Suppl 2:S53-61.

PMID:
11777265
10.

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH.

J Clin Oncol. 2000 Dec 1;18(23):3894-903.

PMID:
11099318
11.

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlović S.

Clin Cancer Res. 2000 Jun;6(6):2175-82.

12.
13.

Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells.

Peshwa MV, Benike C, Dupuis M, Kundu SK, Engleman EG, Merigan TC, van Schooten WC.

Cell Transplant. 1998 Jan-Feb;7(1):1-9.

PMID:
9489758
14.

Development of a bioartificial liver employing xenogeneic hepatocytes.

Hu WS, Friend JR, Wu FJ, Sielaff T, Peshwa MV, Lazar A, Nyberg SL, Remmel RP, Cerra FB.

Cytotechnology. 1997 Jan;23(1-3):29-38. doi: 10.1023/A:1007906512616.

15.

Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals.

Dupuis M, Peshwa MV, Benike C, Kundu SK, Engleman EG, Van Schooten WC, Merigan TC.

AIDS Res Hum Retroviruses. 1997 Jan 1;13(1):33-9.

PMID:
8989425
16.

Generation and ex vivo expansion of HTLV-1 specific CD8+ cytotoxic T-lymphocytes for adoptive immunotherapy.

Peshwa MV, Page LA, Qian L, Yang D, van Schooten WC.

Biotechnol Bioeng. 1996 Jun 5;50(5):529-40.

PMID:
18627015
17.

Tissue engineering, bioartificial organs, and cell therapies: II.

Miller WM, Peshwa MV.

Biotechnol Bioeng. 1996 Jun 5;50(5):463. No abstract available.

PMID:
18627008
18.

Tissue engineering, bioartificial organs, and cell therapies: I.

Miller WM, Peshwa MV.

Biotechnol Bioeng. 1996 May 20;50(4):347-8. No abstract available.

PMID:
18626982
19.

Mechanistics of formation and ultrastructural evaluation of hepatocyte spheroids.

Peshwa MV, Wu FJ, Sharp HL, Cerra FB, Hu WS.

In Vitro Cell Dev Biol Anim. 1996 Apr;32(4):197-203.

PMID:
8727043
20.

Formation of porcine hepatocyte spheroids for use in a bioartificial liver.

Lazar A, Peshwa MV, Wu FJ, Chi CM, Cerra FB, Hu WS.

Cell Transplant. 1995 May-Jun;4(3):259-68.

PMID:
7640865
21.

Entrapment of hepatocyte spheroids in a hollow fiber bioreactor as a potential bioartificial liver.

Wu FJ, Peshwa MV, Cerra FB, Hu WS.

Tissue Eng. 1995 Spring;1(1):29-40. doi: 10.1089/ten.1995.1.29.

PMID:
19877913
22.

Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver.

Nyberg SL, Remmel RP, Mann HJ, Peshwa MV, Hu WS, Cerra FB.

Ann Surg. 1994 Jul;220(1):59-67.

23.

High density culture of mammalian cells with dynamic perfusion based on on-line oxygen uptake rate measurements.

Kyung YS, Peshwa MV, Gryte DM, Hu WS.

Cytotechnology. 1994;14(3):183-90.

PMID:
7765589
24.

Evolution of the bioartificial liver: the need for randomized clinical trials.

Nyberg SL, Peshwa MV, Payne WD, Hu WS, Cerra FB.

Am J Surg. 1993 Nov;166(5):512-21. Review.

PMID:
8238746
25.

Extracorporeal application of a gel-entrapment, bioartificial liver: demonstration of drug metabolism and other biochemical functions.

Nyberg SL, Shirabe K, Peshwa MV, Sielaff TD, Crotty PL, Mann HJ, Remmel RP, Payne WD, Hu WS, Cerra FB.

Cell Transplant. 1993 Nov-Dec;2(6):441-52.

PMID:
8167929
26.

Evaluation of a hepatocyte-entrapment hollow fiber bioreactor: a potential bioartificial liver.

Nyberg SL, Shatford RA, Peshwa MV, White JG, Cerra FB, Hu WS.

Biotechnol Bioeng. 1993 Jan 20;41(2):194-203.

PMID:
18609538
27.

Cultivation of mammalian cells as aggregates in bioreactors: effect of calcium concentration of spatial distribution of viability.

Peshwa MV, Kyung YS, McClure DB, Hu WS.

Biotechnol Bioeng. 1993 Jan 20;41(2):179-87.

PMID:
18609536
28.

Spatial distribution of mammalian cells grown on macroporous microcarriers with improved attachment kinetics.

Lim HS, Han BK, Kim JH, Peshwa MV, Hu WS.

Biotechnol Prog. 1992 Nov-Dec;8(6):486-93.

PMID:
1369034
29.

Entrapment of cultured pancreas islets in three-dimensional collagen matrices.

Chao SH, Peshwa MV, Sutherland DE, Hu WS.

Cell Transplant. 1992;1(1):51-60.

PMID:
1344291
30.

Improved microscopic observation of mammalian cells on microcarriers by fluorescent staining.

Nikolai TJ, Peshwa MV, Goetghebeur S, Hu WS.

Cytotechnology. 1991 Feb;5(2):141-6.

PMID:
1367155

Supplemental Content

Loading ...
Support Center